New guidelines, growth opportunities, and investment in new technologies

Our Press & Policy

Stay up to date with the latest IVD sector news and developments in health policy.


Fast MDx Ltd. achieves ISO 13485:2016 Quality System Certification

26 Oct, 2023 | Return|

October 25, 2023 - London, UK: Fast MDx Ltd, a UK-based molecular diagnostics company who are focussed on the development of medical diagnostics for faster and more accurate diagnosis in healthcare, has announced completion of the ISO 13485:2016 certification.


ISO 13485 is a globally recognised standard, published by the International Standards Organization (ISO), setting out the requirements for quality management systems for diagnostics and medical devices. The ISO quality standard is awarded to manufacturers who demonstrate excellence in quality management and best practice for design, manufacture or supply and hence meeting the regulatory requirements specific to the IVD industry.


Fast MDx Ltd. is a molecular diagnostics company focussed on development of medical diagnostics for faster and more accurate diagnosis in healthcare, announced it has completed the quality management ISO 13485:2016 certification audit for the design and development and manufacture of molecular diagnostic platforms for infectious diseases.  


The completion of the ISO 13485:2016 certification audit exemplifies Fast MDx’s commitment to meeting the highest standards of quality, reliability and safety in the medical device industry.


“ We are very proud to receive the ISO 13485:2016 certification; this achievement demonstrates our continuous commitment to consistently high standards in our quest to deliver the Fast MDx platform.” said Richard Lewis, CEO.


“Fast MDx are focussed on delivering the world’s first, low-cost, high-throughput, near-patient molecular diagnostic test system, and our ISO accreditation is another successful step in the journey.”


About Fast MDx Ltd.


Fast MDx Ltd. is a social enterprise company which provides molecular diagnostic testing that has the potential to benefit society whilst having less impact on the environment. With almost half of the world’s population having little or no access to diagnostics1, the goal is to provide affordable molecular diagnostics in more countries and in more settings.


For more information


Visit the company website at or contact



  1. Fleming KA et al.  The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet. 2021 Nov 27;398(10315):1997-2050. doi: 10.1016/S0140-6736(21)00673-5. Epub 2021


##   END  ##

Interested in becoming a member? Join us!

Copyright 2023 BIVDA Ltd is registered in England
Company Number 2687137
Registered Office is 299 Oxford Street (5th floor),
London, W1C 2DZ. VAT Number 563105858